Serina Cash from 2010 to 2024
| SER Stock | 4.79 0.64 15.42% |
Cash | First Reported 2010-12-31 | Previous Quarter 345 K | Current Value 651.4 K | Quarterly Volatility 919.4 K |
Check Serina Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Serina Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 124.5 K, Total Revenue of 134.9 K or Other Operating Expenses of 6.8 M, as well as many indicators such as Price To Sales Ratio of 148, Dividend Yield of 0.0 or PTB Ratio of 2.58. Serina financial statements analysis is a perfect complement when working with Serina Therapeutics Valuation or Volatility modules.
Serina | Cash |
Latest Serina Therapeutics' Cash Growth Pattern
Below is the plot of the Cash of Serina Therapeutics over the last few years. Cash refers to the most liquid asset of Serina Therapeutics, which is listed under current asset account on Serina Therapeutics balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from Serina Therapeutics customers. The amounts must be unrestricted with restricted cash listed in a different Serina Therapeutics account. It is the total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts. Serina Therapeutics' Cash historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Serina Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Cash | 10 Years Trend |
|
Cash |
| Timeline |
Serina Cash Regression Statistics
| Arithmetic Mean | 1,726,030 | |
| Geometric Mean | 1,361,869 | |
| Coefficient Of Variation | 53.27 | |
| Mean Deviation | 834,627 | |
| Median | 2,352,000 | |
| Standard Deviation | 919,425 | |
| Sample Variance | 845.3B | |
| Range | 2M | |
| R-Value | (0.81) | |
| Mean Square Error | 312B | |
| R-Squared | 0.66 | |
| Significance | 0.0002 | |
| Slope | (166,675) | |
| Total Sum of Squares | 11.8T |
Serina Cash History
Other Fundumenentals of Serina Therapeutics
Serina Therapeutics Cash component correlations
Click cells to compare fundamentals
About Serina Therapeutics Financial Statements
Serina Therapeutics shareholders use historical fundamental indicators, such as Cash, to determine how well the company is positioned to perform in the future. Although Serina Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Serina Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Serina Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Cash | 345 K | 651.4 K | |
| Cash And Short Term Investments | 345 K | 327.8 K | |
| Change In Cash | -300 K | -315 K | |
| Free Cash Flow | -7.8 M | -8.2 M | |
| Begin Period Cash Flow | 645 K | 612.8 K | |
| Other Cashflows From Financing Activities | 17.5 M | 18.4 M | |
| Other Non Cash Items | 6.2 M | 6.6 M | |
| Total Cash From Operating Activities | -7.8 M | -8.2 M | |
| Total Cash From Financing Activities | 17.5 M | 18.4 M | |
| End Period Cash Flow | 345 K | 651.4 K | |
| Other Cashflows From Investing Activities | -9 M | -8.6 M | |
| Free Cash Flow Yield | (0.53) | (0.50) | |
| Operating Cash Flow Per Share | (7.23) | (7.59) | |
| Free Cash Flow Per Share | (7.23) | (7.59) | |
| Cash Per Share | 0.32 | 0.30 | |
| EV To Operating Cash Flow | (2.42) | (2.54) | |
| EV To Free Cash Flow | (2.42) | (2.54) | |
| Price To Operating Cash Flows Ratio | (1.90) | (2.00) | |
| Price To Free Cash Flows Ratio | (1.90) | (2.00) | |
| Cash Ratio | 0.06 | 0.06 | |
| Cash Conversion Cycle | -2.9 K | -2.7 K | |
| Operating Cash Flow Sales Ratio | (54.93) | (57.68) | |
| Free Cash Flow Operating Cash Flow Ratio | 1.00 | 1.16 | |
| Cash Flow Coverage Ratios | (1.79) | (1.88) | |
| Price Cash Flow Ratio | (1.90) | (2.00) | |
| Cash Flow To Debt Ratio | (1.79) | (1.88) |
Pair Trading with Serina Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Serina Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Serina Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Serina Stock
Moving against Serina Stock
| 0.73 | GILD | Gilead Sciences | PairCorr |
| 0.71 | BMY | Bristol Myers Squibb | PairCorr |
| 0.62 | DYAI | Dyadic International | PairCorr |
| 0.53 | ESPR | Esperion Therapeutics Buyout Trend | PairCorr |
The ability to find closely correlated positions to Serina Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Serina Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Serina Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Serina Therapeutics to buy it.
The correlation of Serina Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Serina Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Serina Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Serina Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Serina Stock Analysis
When running Serina Therapeutics' price analysis, check to measure Serina Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Serina Therapeutics is operating at the current time. Most of Serina Therapeutics' value examination focuses on studying past and present price action to predict the probability of Serina Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Serina Therapeutics' price. Additionally, you may evaluate how the addition of Serina Therapeutics to your portfolios can decrease your overall portfolio volatility.